Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptors, OX40 | 1 | 2024 | 44 | 0.930 |
Why?
|
OX40 Ligand | 1 | 2024 | 55 | 0.910 |
Why?
|
Coronary Vasospasm | 1 | 2019 | 81 | 0.650 |
Why?
|
Guillain-Barre Syndrome | 1 | 2018 | 127 | 0.560 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2019 | 646 | 0.510 |
Why?
|
Immunotherapy | 5 | 2024 | 4652 | 0.470 |
Why?
|
Immunoconjugates | 1 | 2020 | 954 | 0.420 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 179 | 0.400 |
Why?
|
Hematopoietic Stem Cell Transplantation | 7 | 2024 | 5671 | 0.380 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 1405 | 0.350 |
Why?
|
Paraproteinemias | 2 | 2023 | 248 | 0.350 |
Why?
|
Multiple Myeloma | 7 | 2023 | 5146 | 0.340 |
Why?
|
Esophageal Neoplasms | 1 | 2019 | 1654 | 0.320 |
Why?
|
Transplantation, Autologous | 6 | 2022 | 2115 | 0.300 |
Why?
|
Nephrectomy | 2 | 2024 | 937 | 0.200 |
Why?
|
Adenocarcinoma | 1 | 2019 | 6346 | 0.200 |
Why?
|
Heterocyclic Compounds | 1 | 2022 | 246 | 0.190 |
Why?
|
Bronchoalveolar Lavage | 1 | 2020 | 128 | 0.180 |
Why?
|
Budesonide | 1 | 2021 | 157 | 0.170 |
Why?
|
Neoplasms | 3 | 2024 | 22170 | 0.170 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2020 | 242 | 0.160 |
Why?
|
Carcinoma, Renal Cell | 2 | 2024 | 3164 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11742 | 0.150 |
Why?
|
Nitroglycerin | 1 | 2019 | 329 | 0.150 |
Why?
|
Organoplatinum Compounds | 1 | 2019 | 407 | 0.150 |
Why?
|
Leucovorin | 1 | 2019 | 643 | 0.140 |
Why?
|
Antigens, CD19 | 1 | 2020 | 424 | 0.140 |
Why?
|
Kidney Neoplasms | 2 | 2024 | 4249 | 0.140 |
Why?
|
Prostatic Neoplasms | 3 | 2024 | 11118 | 0.130 |
Why?
|
Steroids | 1 | 2021 | 929 | 0.130 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 686 | 0.120 |
Why?
|
Warfarin | 2 | 2021 | 1483 | 0.120 |
Why?
|
Precancerous Conditions | 1 | 2022 | 980 | 0.120 |
Why?
|
Vasodilator Agents | 1 | 2019 | 973 | 0.120 |
Why?
|
Biological Evolution | 1 | 2020 | 1071 | 0.120 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2219 | 0.120 |
Why?
|
Fluorouracil | 1 | 2019 | 1641 | 0.120 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2018 | 664 | 0.110 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13639 | 0.110 |
Why?
|
Lymphocytes | 1 | 2021 | 2612 | 0.110 |
Why?
|
Anti-Inflammatory Agents | 1 | 2021 | 1809 | 0.100 |
Why?
|
Venous Thrombosis | 1 | 2021 | 1303 | 0.090 |
Why?
|
Kidney Diseases | 1 | 2022 | 2091 | 0.090 |
Why?
|
Hematopoietic Stem Cell Mobilization | 2 | 2022 | 225 | 0.090 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1469 | 0.090 |
Why?
|
Myelodysplastic Syndromes | 1 | 2020 | 1394 | 0.090 |
Why?
|
Humans | 28 | 2024 | 761504 | 0.090 |
Why?
|
Thrombosis | 1 | 2023 | 2942 | 0.080 |
Why?
|
Gene Expression | 1 | 2021 | 7581 | 0.080 |
Why?
|
Brain Neoplasms | 2 | 2021 | 9031 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3767 | 0.080 |
Why?
|
Genomics | 2 | 2021 | 5821 | 0.080 |
Why?
|
Retrospective Studies | 11 | 2024 | 80636 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1866 | 0.070 |
Why?
|
Hemorrhage | 1 | 2019 | 3424 | 0.070 |
Why?
|
Anticoagulants | 2 | 2021 | 4812 | 0.070 |
Why?
|
Aged | 11 | 2024 | 169289 | 0.070 |
Why?
|
Electrocardiography | 1 | 2019 | 6377 | 0.070 |
Why?
|
Male | 14 | 2024 | 360804 | 0.060 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13380 | 0.060 |
Why?
|
Middle Aged | 10 | 2024 | 220895 | 0.050 |
Why?
|
Transplantation Conditioning | 2 | 2020 | 1590 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 12974 | 0.050 |
Why?
|
Bipolar Disorder | 1 | 2019 | 5092 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9177 | 0.050 |
Why?
|
Atrial Fibrillation | 1 | 2019 | 5127 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 629 | 0.040 |
Why?
|
Myeloablative Agonists | 1 | 2020 | 209 | 0.040 |
Why?
|
Pneumocystis carinii | 1 | 2020 | 72 | 0.040 |
Why?
|
Aged, 80 and over | 5 | 2024 | 58976 | 0.040 |
Why?
|
Melphalan | 1 | 2020 | 420 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2021 | 64680 | 0.040 |
Why?
|
Enoxaparin | 1 | 2021 | 391 | 0.040 |
Why?
|
Interleukin-8 | 1 | 2021 | 695 | 0.040 |
Why?
|
Stroke | 1 | 2019 | 9757 | 0.040 |
Why?
|
Prognosis | 3 | 2022 | 29625 | 0.030 |
Why?
|
ras Proteins | 1 | 2021 | 1054 | 0.030 |
Why?
|
Cranial Irradiation | 1 | 2018 | 390 | 0.030 |
Why?
|
Dexamethasone | 1 | 2022 | 1948 | 0.030 |
Why?
|
Adult | 7 | 2024 | 221177 | 0.030 |
Why?
|
DNA Damage | 1 | 2024 | 2446 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2023 | 4915 | 0.030 |
Why?
|
Antibodies, Viral | 1 | 2024 | 3156 | 0.030 |
Why?
|
Animals | 1 | 2024 | 168459 | 0.020 |
Why?
|
Incidence | 2 | 2021 | 21353 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3639 | 0.020 |
Why?
|
Vaccination | 1 | 2024 | 3384 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2917 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4853 | 0.020 |
Why?
|
Medical Oncology | 1 | 2021 | 2321 | 0.020 |
Why?
|
Radiosurgery | 1 | 2018 | 1342 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10090 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54425 | 0.020 |
Why?
|
Mutation | 2 | 2024 | 30052 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2020 | 3396 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2021 | 12059 | 0.020 |
Why?
|
Recurrence | 1 | 2018 | 8465 | 0.020 |
Why?
|
Female | 5 | 2024 | 392644 | 0.020 |
Why?
|
Risk Factors | 2 | 2021 | 74206 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 15936 | 0.010 |
Why?
|
Melanoma | 1 | 2018 | 5709 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 23995 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39106 | 0.010 |
Why?
|
Concepts
(103)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(5)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_